Here’s what you should know.
1. Allergan’s linaclotide delayed release clinical data will focus on abdominal pain in irritable bowel syndrome with constipation.
2. Its Linzess data will focus on treatment satisfaction comparing an indirect treatment comparison and stool consistency and frequency data.
3. Allergan’s Viberzi data will focus on the drug’s effectiveness in treating irritable bowel syndrome with diarrhea.
4. Finally, its relamorelin data will focus on gastroparesis and cenicriviroc products to treat non-alcoholic steatohepatitis.
More articles on gastroenterology:
Gastrointestinal Specialists join Hampton Physicians Group — 3 insights
Gastro Health acquires Dr. Orlando Torres’ practice: 3 key notes
GI leader to know: Dr. Stephen Hutto of NorthPark Medical Plaza
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.